Arvinas Inc
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma G12D protein for the treatment of cancers with the G12D mutation comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), which are investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
- Ticker
- ARVN
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- -
- Headquarters
- 5 Science Park, New Haven, CT, United States, 06511
- Employees
- 246
- Website
- arvinas.com
Metrics
Analyst Insights & forecasts
Based on information from 15 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$1.10 | -$0.90 | $2.58 |
| Expected | -$0.57 | -$0.96 | -$0.24 |
| Surprise | -92.98% | 6.65% | 1,175.00% |
| Missed | Beat | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $250M | $0.5M | -99.80% |
| Net income | $169M | $-53.9M | -131.82% |
| Profit margin | 67.84% | -10,780.00% | -15,990.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Arvinas Inc share?
Arvinas Inc shares are currently traded for undefined per share.
02How many shares does Arvinas Inc have?
Arvinas Inc currently has 65.5M shares.
03Does Arvinas Inc pay dividends?
No, Arvinas Inc doesn't pay dividends.
04What is Arvinas Inc 52 week high?
Arvinas Inc 52 week high is $14.51.
05What is Arvinas Inc 52 week low?
Arvinas Inc 52 week low is $6.33.
06What is the 200-day moving average of Arvinas Inc?
Arvinas Inc 200-day moving average is $9.29.
07Who is Arvinas Inc CEO?
The CEO of Arvinas Inc is -.
08How many employees Arvinas Inc has?
Arvinas Inc has 246 employees.
09What is the market cap of Arvinas Inc?
The market cap of Arvinas Inc is $441M.
10What is the P/E of Arvinas Inc?
The current P/E of Arvinas Inc is null.
11What is the EPS of Arvinas Inc?
The EPS of Arvinas Inc is -$0.08.
12What is the PEG Ratio of Arvinas Inc?
The PEG Ratio of Arvinas Inc is null.
13What do analysts say about Arvinas Inc?
According to the analysts Arvinas Inc is considered a hold.


